Recombinant human brain natriuretic peptide therapy combined with bone mesenchymal stem cell transplantation for treating heart failure in rats

Zhang,Junbiao; Zhang,Ligong; Wu,Qingwu; Liu,Hui; Huang,Luli

doi:10.3892/mmr.2012.1185

Recombinant human brain natriuretic peptide therapy combined with bone mesenchymal stem cell transplantation for treating heart failure in rats

Authors:
- Junbiao Zhang
- Ligong Zhang
- Qingwu Wu
- Hui Liu
- Luli Huang
View Affiliations

Affiliations: The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, P.R. China
Published online on: November 15, 2012 https://doi.org/10.3892/mmr.2012.1185
Pages: 628-632

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to investigate the effects of combined recombinant human brain natriuretic peptide (rhBNP) therapy and bone mesenchymal stem cell (BMSC) transplantation on cell survival in myocardial tissues and on heart function in a rat model of heart failure (HF). Rat BMSCs were isolated, amplified and adherent cultured in vitro. A rat model of HF was established via the intraperitoneal injection of doxorubicin (Adriamycin). The rats were randomly divided into normal, HF, BMSC, rhBNP and BMSC plus rhBNP groups. The BMSCs were administered once via tail vein injection and rhBNP was infused via the jugular vein. Echocardiography and polygraphy were used to evaluate heart function. An enzyme‑linked immunosorbent assay was used to detect the changes in brain natriuretic peptide (BNP) concentration prior to and following intervention. Western blot analysis was used to detect the expression of the myocardium‑specific proteins GATA-binding protein 4 (GATA-4), connexin 43 (Cx43) and cardiac troponin I (cTnI). The results of cardiac echocardiography and the hemodynamic data show that various indicators of left ventricular systolic function in the BMSC plus rhBNP group were significantly improved compared with those in the other groups (P<0.05). No significant differences in the improvement of cardiac function were observed between the BMSC and rhBNP groups (P>0.05). Following treatment, a significant difference in BNP levels was observed between the BMSC plus rhBNP and the BMSC groups (P<0.05). The GATA-4, Cx43 and cTnI expression levels in the BMSC plus rhBNP group were higher than those in the BMSC group. Compared with rhBNP treatment, BMSC transplantation alone does not significantly improve heart function. However, combining rhBNP therapy and BMSC transplantation increases the expression levels of GATA-4 and other proteins to improve cardiac systolic and diastolic function.

View Figures

View References

1	Xu XW, Zeng GY, Yang Y and Liu HX: Recombinant human brain natriuretic peptide on the cardiac hemodynamics and renal function in dogs with heart failure. Yao Xue Xue Bao. 37:758–762. 2002.(In Chinese).
2	Iglesias J, Hom D, Antoniotti M, Ayoub S and Levine JS: Predictors of worsening renal function in adult patients with congestive heart failure receiving recombinant human B-type brain natriuretic peptide (nesiritide). Nephrol Dial Transplant. 21:3458–3465. 2006. View Article : Google Scholar
3	Recombinant Human Brain Natriuretic Peptide Multicenter Clinical Study Group. Hu DY: Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with decompensated acute heart failure: a multicenter, randomized, open label, controlled study. Zhonghua Xin Xue Guan Bing Za Zhi. 39:305–308. 2011.(In Chinese).
4	Hatzistergos KE, Quevedo H, Oskouei BN, et al: Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 107:913–922. 2010. View Article : Google Scholar : PubMed/NCBI
5	Wei H, Tan G, Manasi, et al: One-step derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cells. Stem Cell Res. 9:87–100. 2012. View Article : Google Scholar : PubMed/NCBI
6	Gnecchi M, Danieli P and Cervio E: Mesenchymal stem cell therapy for heart disease. Vascul Pharmacol. 57:48–55. 2012. View Article : Google Scholar : PubMed/NCBI
7	Li XH, Fu YH, Lin QX, et al: Induced bone marrow mesenchymal stem cells improve cardiac performance of infarcted rat hearts. Mol Biol Rep. 39:1333–1342. 2012. View Article : Google Scholar : PubMed/NCBI
8	Vassalli G and Moccetti T: Cardiac repair with allogeneic mesenchymal stem cells after myocardial infarction. Swiss Med Wkly. 141:w132092011.PubMed/NCBI
9	Wen Z, Zheng S, Zhou C, Wang J and Wang T: Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. J Cell Mol Med. 15:1032–1043. 2011. View Article : Google Scholar : PubMed/NCBI
10	Tokunaga M, Liu ML, Nagai T, et al: Implantation of cardiac progenitor cells using self-assembling peptide improves cardiac function after myocardial infarction. J Mol Cell Cardiol. 49:972–983. 2010. View Article : Google Scholar : PubMed/NCBI
11	Hilfiker A, Kasper C, Hass R and Haverich A: Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation? Langenbecks Arch Surg. 396:489–497. 2011. View Article : Google Scholar : PubMed/NCBI
12	Menasche P: Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol. 50:258–265. 2011. View Article : Google Scholar : PubMed/NCBI
13	Siveski-Iliskovic N, Hill M, Chow DA and Singal PK: Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 91:10–15. 1995. View Article : Google Scholar : PubMed/NCBI
14	Oh Y, Wei H, Ma D, Sun X and Liew R: Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine. Heart. 98:443–449. 2012. View Article : Google Scholar : PubMed/NCBI
15	Hoover-Plow J and Gong Y: Challenges for heart disease stem cell therapy. Vasc Health Risk Manag. 8:99–113. 2012. View Article : Google Scholar : PubMed/NCBI
16	Arnous S, Mozid A, Martin J and Mathur A: Bone marrow mononuclear cells and acute myocardial infarction. Stem Cell Res Ther. 3:22012. View Article : Google Scholar : PubMed/NCBI
17	Mills RM, LeJemtel TH, Horton DP, et al: Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 34:155–162. 1999. View Article : Google Scholar
18	Bocchi EA, Moura LZ, Issa VS, Cruz F, Carvalho VO and Guimarães GV: Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure. Cardiovasc Ther. Aug 3–2011.(Epub ahead of print). View Article : Google Scholar
19	Iglesias J, Hom D, Antoniotti M, Ayoub S and Levine JS: Predictors of worsening renal function in adult patients with congestive heart failure receiving recombinant human B-type brain natriuretic peptide (nesiritide). Nephrol Dial Transplant. 21:3458–3465. 2006. View Article : Google Scholar
20	Calderone A, Thaik CM, Takahashi N, Chang DL and Colucci WS: Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 101:812–818. 1998. View Article : Google Scholar : PubMed/NCBI
21	Kawakami R, Saito Y, Kishimoto I, et al: Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation. 110:3306–3312. 2004. View Article : Google Scholar